Oncotarget recently published “Heterogeneity of CEACAM5 in breast cancer” which reported that Here, we examined a repository of 110 cryopreserved primary breast carcinomas by immunohistochemistry to assess the distribution of CEACAM5 in tumor subtypes.
Assessing sample sets of paired primary breast cancers and corresponding lymph node lesions from a total of 59 patients revealed a high correlation between primary tumor and lymph node with regard to CEACAM5-status.
When examining the consequence of expression of CEACAM5 in breast cancer cell lines in culture assays we found that CEACAM5-expressing cells were less invasive. [Read more…] about Oncotarget: Heterogeneity of CEACAM5 in breast cancer
Related Posts
- 40Biomarkers that have proven to be predictors of immunotherapy responses in melanoma patients have also been shown to be clinically relevant in breast cancer patients. Clinical cancer research.. This study found that this biomarker, a molecule called major histocompatibility complex class II protein (MHC-II), Immunotherapy Two types of benefits chest…